Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Sahil Manocha
Period: Reporting period mapped to calendar 2024 Q4.
- Questions
- 3on tracked calls
- Challenge rate
- 0%none of 3 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 1with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 3 of 3 questions from 2 companies
AMEAmetek2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2024 Q4
Can you provide any context on the $85 million in growth investments? How is that split between segment
Show response
Growth investments ~2/3 RD&E, ~1/3 sales and marketing. Biased toward EIG due to segment size. Incremental spend down slightly from $90M to $85M.
Could you discuss the new product intros that you're most excited about for 2025? And how do you see the vitality index trending?
Show response
Vitality index hit 30% in Q4, one of highest readings. Started in low-mid teens years ago. New products support premium pricing and open adjacent markets.
JCIJohnson Controls1 question · 1 reporting period · 0 of 1 challenging
Calendar 2024 Q4
How are you thinking about capital deployment priorities in the current environment?
Show response
100% FCF return to shareholders via dividends and buybacks. Divestiture proceeds also returned to shareholders unless material M&A opportunity arises.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| AME Ametek | 2 | —Rate withheld: fewer than 3 questions |
| JCI Johnson Controls | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 3 | 0%none of 3 questions | 2 |
- 2024 Q43 questions · challenge rate 0% (none of 3 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Innovation & R&D2
- Capital Allocation1
- Capex Investment1
- Product Launch1